A Phase 4 interventional study of Angiotensin II and hydrocortisone sodium succinate in Septic Shock, Shock and Sepsis, sponsored by Kingman Regional Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.
Sponsored by Kingman Regional Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Angiotensin II in Shock, Septic — 4 open to participants now, 5 under way, none of them phase 3. Angiotensin II · Shock, Septic.
Among the 12 studies testing Angiotensin II in Shock, Septic, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 6 in phase 4, and was the 8th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →4 of the 12 studies testing Angiotensin II in Shock, Septic are open now, in 2 countries. Recruiting first, the newest first:
Brett A Faine · Sites in United States
Ages 18–99
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Angiotensin II: first FDA approval 2017 (GIAPREZA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 30 across the 12 interventional studies. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
Kingman Regional Medical Center is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Kingman Regional Medical Center has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Angiotensin II in Shock, Septic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06693726Brett A FaineEarly Angiotensin II in the Emergency Department | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Angiotensin II in Shock, Septic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy.
The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynamic response 6 hours after initiation. The purpose of this study is to evaluate the efficacy of angiotensin-II when used as the second vasopressor agent for septic shock.
Objectives:
Primary Objective:
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Angiotensin II Other Names: Giapreza
Drug: Angiotensin II and hydrocortisone sodium succinate
Drug pages: Angiotensin IIStudies of Angiotensin IIAngiotensin II pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Hydrocortisone hemisuccinateStudies of Hydrocortisone hemisuccinateHydrocortisone hemisuccinate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
Also known as: Giapreza
The incidence of hemodynamic response, defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 1 hour after initiation of angiotensin-II
Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 1 hour after initiation of angiotensin-II.
Time frame: 1 hour
The incidence of hemodynamic response at 3 hours after initiation of angiotensin-II
Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 3 hours after initiation of angiotensin-II.
Time frame: 3 hours
The incidence of hemodynamic response at 6 hours after initiation of angiotensin-II
Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 6 hours after initiation of angiotensin-II.
Time frame: 6 hours
28-day mortality
Defined as all cause mortality up to 28 days from study enrollment.
Time frame: 28 days
ICU length of stay
Defined as the time spent within the ICU until discharge to a step down unit.
Time frame: 1 year
Need for renal replacement therapy
Defined as patients started on either continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) during the study period.
Time frame: 1 year
Vasoactive medication duration overall
Defined as the duration (hours) of vasoactive medication use during the study period.
Time frame: 1 year
Incidence of adverse reactions
Define as an unexpected or unintended effect suspected to be caused by a medicine.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.
Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 12 months is below that.
Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Angiotensin II · Hydrocortisone hemisuccinate
Kingman Regional Medical Center